Hybrid nanostructures are nanoparticles which incorporate two or more structures. These structures may represent organic or inorganic material, but they synergistically improve the application of the material for end users. Hybrid Nanostructures for Cancer Theranostics explores how hybrid nanostructures are used in cancer treatment.
Focusing on the properties of hybrid nanostructures, the book demonstrates how their unique characteristics can be used to create more effective treatment techniques. In the second half of the book, the chapters examine how hybrid nanostructures are currently being used in practice, assessing the pros and cons of using different types of nanostructures for different treatments.
This valuable resource will allow readers to understand the core and emerging concept of functionalization, bioconjugation, hyperthermia and phototherapy of nanoparticles which allows for the greater use of hybrid nanomaterials in cancer theranostics.
Ashok Bohara, Raghvendra: - Dr. Raghvendra A Bohara, MSc, PhD, is currently working as Assistant Professor in Centre for Interdisciplinary Research, D. Y. Patil Education society (Deemed to be university) Kolhapur, India and Government of Ireland IRC Postdoctoral fellow in CÚRAM, Centre for Research in Medical Devices, National University of Ireland Galway, Ireland. He is associated with Prof. Abhay Pandit (www.curamdevices.ie/) for his postdoctoral research. He is a recipient of various prestigious fellowships including Government of India, Indian Council of Medical Research Fellowship (ICMR) Fellowship in RMRC Belagavai, Government of Ireland IRC fellowship Ireland 2017. His research work has attracted excellent collaboration and with many colleague in India, South Korea, Japan, Taiwan and Ireland with whom he has co-authored his publications. In addition to his current research, he has been deeply engaged in collaborative work with the many eminent scientists from Japan, USA, Germany, Korea, Ireland, India, Poland, Saudi Arabia and Australia. Dr. Bohara has published 28 peer reviewed journal articles and 4 book chapters (total citations 400 H index: 11), . He has received international acclaims and awards for research contribution, generated research fund in excess of > 100,000, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of wider community. Dr Bohara also actively involved in teaching MSC Stem cells and Regenerative medicine and Medical Biotechnology Currently he is Supervising 1 Ph.D. student and co-supervising 2 PhD students in Centre for Interdisciplinary Research, D. Y. Patil Education society (Deemed to be university) Kolhapur, India. Dr Bohara is recipient of prestigious awards such as, Government of India, SERB Travel grant Young Scientist Awardee (2). Excellence in Research Award for the year 2016-2017 awarded by D. Y. Patil Education society (Deemed to be university) Kolhapur, India. Dr Bohara is a member of Institutional ethical committee, In charge Research and Innovations for Comprehensive health care (RICH) Cell, Member Research Guidance clinic and also heading the responsibility of plagiarism policy of the university. He is the Associate Editor for Biochemistry and Biophysics Reports from Elsevier. He has successfully worked as guest editor and reviewers for many journals. His major thrust areas includes magnetic triggered drug delivery and cancer Nano medicine.
Thorat, Nanasaheb D.: -
Dr. Nanasaheb Thorat is Principal Investigator funded by the Science Foundation Ireland (SFI) and Irish Research Council (IRC) Pathway Program at the University of Limerick, Ireland. He is also a Marie Curie Visiting Research Scientist at the University of Oxford, UK.
He has been deeply engaged in collaborative work with the many eminent scientists from Japan, USA, Germany, Korea, Ireland, India, Poland, Saudi Arabia and Australia. Dr. Thorat has received the European Commission's innovation Radar "Grand Prix of the Innovation Radar Prize 2020" for developing ground-breaking technology for breast cancer theranostics.
